To our partners and stakeholders,
The Sofwave family is appalled by the unconscionable actions that have transpired in Israel in recent days. We stand in solidarity with the victims of these horrific terrorist acts, and we express our deepest condolences, thoughts and prayers to those impacted.
We are focused on the well-being of our Israeli employees, providing them with the support required. While events in Israel are evolving, our global activity and the supply of our products are expected to continue as planned. We are monitoring the situation closely and will provide updates if and when needed.
We thank all of our partners and stakeholders that have reached out to express their support and best wishes and are grateful for their continued confidence in Sofwave.
Louis Scafuri
CEO, Sofwave Medical
Presentations
Sofwave Medical reports financial results for the second quarter and first half of the fiscal year 2024 and recent business highlights. The second quarter’s revenue was $14.6M, +18% year-over-year growth, recurring revenue was $6.0M and +83% year-over-year increase. First-half IFRS and Non-IFRS operating loss continue to narrow substantially and decrease YoY by 66% and 80%, respectively. Sofwave continues to expect to achieve operating break-even in 2024.
Sofwave Medical reports financial results for the first quarter of fiscal year 2024 and recent business highlights. First quarter revenue of $13.2M, +27% year-over-year growth and recurring revenue of $4.7M, +118% year-over-year increase with over 280,000 treatments performed since initial approval. We are happy to report our recent FDA clearance and launch of Pure Impact™, a strength and muscle toning body module utilizing PlyoPulse™ EMS technology.
Sofwave Medical reports financial results for the third quarter of fiscal year 2023, for the period ended September 30, 2023, and recent business highlights. During the First nine months, we have reached a revenue of $35.0M, +60% year-over-year growth with a gross margin of 73.8%, and pulse recurring revenue of $3.1M, +99% year-over-year growth with over 185,000 treatments performed worldwide. We are also happy to report that we have obtained FDA clearance for treating acne scars, the “Precise” SUPERB™ applicator, and Sofwave Smart™ IoT Module.
Sofwave Medical Reports Second Quarter and First Half 2023 Financial results with continued growth in revenue and narrow in operating loss. Second quarter revenue of $12.4M, +53% year-over-year growth. First-half revenue of $22.8M, +67% year-over-year growth. Operating loss significantly narrows in both the second quarter and first half periods and moves closer to reaching operating break-even.
This exclusive webinar brings together our Sofwave™ management and investors with Dr. David Goldberg to discuss our unique technology, FDA indications, practice ROI and compares our proprietary SUPERB™ technology with existing treatments in the market.
Please note that the following webinar is in both Hebrew and English.
Sofwave™ Medical LTD reports financial results for the period of January – June 2022 (H1/2022) with accelerated growth in revenues and gross margin. The first half of 2022 revenues reached $13.7 million, an increase of 34% YoY growth, and $2.9 million in recurring revenue from our pulse sales, representing 202% YoY growth. This increase was primarily attributed to the continued marketing and sales investments in the Company’s primary markets and increased demand for the Company’s solutions. To learn more, please watch the video.
Press Releases
Stock Exchange Updates
Sofwave Company Profile
Commitment & Passion
Driven by experience and passion, Sofwave Medical is a fast-growing medical aesthetic technology innovator committed to developing cutting-edge technologies for the global aesthetic market.
Game-Changing Approach
Sofwave Medical’s breakthrough technology brings a new standard of care to aesthetic treatments, providing physicians with smart yet simple, effective and safe aesthetic treatments for their patients.
Heritage of Innovation
From key founders of the aesthetic industry, Sofwave Medical brings a novel approach to non-invasive skin treatments using proprietary Synchronous Ultrasound Parallel Beam Technology SUPERB™.
